Adjuvants for allergy vaccines

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1492-1498

  Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

Adjuvant; Allergen vaccine; Immunopotentiator; Sublingual immunotherapy; Vector system

Indexed keywords

EID: 84868284666     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21688     Document Type: Review

References (54)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 177:1572-3; http://dx.doi.org/10.1016/S0140-6736(00)78276-6.
2. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 178:814-7; http://dx.doi.org/10.1016/S0140-6736(01)40417-X.
3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62; PMID:9802362; http://dx.doi.org/10.1016/S0091-6749(98)70271-4.
4. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27, quiz 28-9; PMID:21211639; http://dx.doi.org/10.1016/j.jaci.2010.11.030.
5. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120(Suppl):S25-85.http:// dx.doi.org/10.1016/j.jaci.2007.06.019; PMID:17765078
6. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(Suppl):S147-334; PMID:11707753; http://dx.doi.org/10.1067/mai. 2001.118891; http://dx.doi.org/10.1067/mai.2001.118891.
7. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004; 34:1373-8; PMID:15347369; http://dx.doi.org/10. 1111/j.1365-2222.2004.02052.x.
8. Mascarell L, Van Overtvelt L, Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am 2006; 26:283-306, vii-viii; PMID:16701145; http://dx.doi.org/10.1016/j. iac.2006.02.009.
9. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64(Suppl 91):1-59; PMID:20041860; http://dx.doi.org/10.1111/ j.1398-9995.2009.02309.x.
10. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003; CD002893; PMID:12804442.
11. Passalacqua G, Lombardi C, Troise C, Canonica GW. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol 2009; 41:163-70; PMID:20128229.
12. Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, Mascarell L. Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am 2011; 31:407-19, xii; PMID:21530828; http://dx.doi.org/10.1016/j.iac.2011.03. 001.
13. Wheeler AW, Woroniecki SR. Immunological adjuvants in allergy vaccines: Past, present and future. Allergol Int 2001; 50:295-301; http://dx.doi.org/10. 1046/j.1440-1592.2001.00230.x.
14. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119:826-30; PMID:17335886; http://dx.doi.org/10.1016/ j.jaci.2007.01.025.
15. Crameri R, Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006; 18:761-8; PMID:17010585; http://dx.doi.org/10.1016/j.coi.2006.09.001.
16. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines. Immunol Cell Biol 2004; 82:617-27; PMID:15550120; http://dx.doi.org/10.1111/j.1440- 1711.2004.01288.x.
17. Chapman MD, Wunschmann S, Pomes A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep 2007; 7:363-7; PMID:17697645; http://dx.doi.org/10.1007/ s11882-007-0055-6.
18. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:777-83; PMID:12704357; http://dx.doi.org/10.1067/mai.2003.1338.
19. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34, quiz 1035; PMID:15208578; http://dx.doi.org/10.1016/j.jaci.2004.03.024.
20. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65; PMID:16409190; http://dx.doi.org/10.1111/j.1398-9995.2006.01002.x.
21. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61; PMID:12789226; http://dx.doi.org/10.1067/mai.2003.1570.
22. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65; PMID:8648033; http://dx.doi.org/10.1016/S0091-6749(96)70205-1.
23. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120:278-85; PMID:17531296; http://dx.doi.org/10.1016/j.jaci.2007.04.009.
24. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003; 33:1171-4; PMID:12956735; http://dx.doi.org/10.1046/j.1365-2222.2003.01765.x.
25. Durham SR, Varney VA, Gaga M, Jacobson MR, Varga EM, Frew AJ, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999; 29:1490-6; PMID:10520076; http://dx.doi.org/10.1046/j.1365- 2222.1999.00678.x.
26. Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B, Bieber T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-74, e1; PMID:18036651; http://dx.doi.org/10.1016/j.jaci.2007.09.045.
27. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-9, e5; PMID:18774396; http://dx.doi.org/10.1016/j.jaci.2008.06.034.
28. Zuany-Amorim C, Manlius C, Trifilieff A, Brunet LR, Rook G, Bowen G, et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 2002; 169:1492-9; PMID:12133976.
29. Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB, et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003; 33:2717-26; PMID:14515255; http://dx.doi.org/10.1002/eji.200323329.
30. Trujillo-Vargas CM, Mayer KD, Bickert T, Palmetshofer A, Grunewald S, Ramirez-Pineda JR, et al. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergeninduced T-helper type 2 responses. Clin Exp Allergy 2005; 35:1003-13; PMID:16120081; http://dx.doi.org/10.1111/j.1365-2222.2005.02287.x.
31. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109:455-62; PMID:11897991; http://dx.doi.org/10.1067/mai.2002.122156.
32. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B, et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005; 35:1591-8; PMID:16393325; http://dx.doi.org/10.1111/j.1365-2222.2005.02384.x.
33. Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout AJ. 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-β. J Immunol 2008; 180:5211-21; PMID:18390702.
34. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505; PMID:11421893; http://dx.doi.org/10.1034/j.1398-9995. 2001.056006498.x.
35. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208; PMID:12956739; http://dx.doi.org/10.1046/j.1365-2222. 2003.01699.x.
36. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al.; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-55; PMID:17021320; http://dx.doi.org/10.1056/NEJMoa052916.
37. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy 2009; 39:1830-41; PMID:19817753; http://dx.doi.org/10.1111/j. 1365-2222.2009.03357.x.
38. Scholl I, Weissenbock A, Forster-Waldl E, Untersmayr E, Walter F, Willheim M, et al. Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004; 34:315-21; PMID:14987314; http://dx.doi.org/10. 1111/j.1365-2222.2004.01884.x.
39. Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol Cell Biol 2005; 83:119-28; PMID:15748208; http://dx.doi.org/10.1111/j.1440-1711.2005.01319.x.
40. Kim N, Kwon SS, Lee J, Kim S, Yoo TJ. Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy. Clin Mol Allergy 2006; 4:1-9; PMID:16478539; http://dx.doi.org/10.1186/1476-7961-4-4.
41. Terada T. New therapeutic strategies: a chimeric human-cat fusion protein inhibits allergic reactivity. Clin Exp Allergy 2006; 6:96-100; http://dx.doi.org/10.1111/j.1365-2222.2006.00108.x.
42. Gerstmayr M, Ilk N, Jahn-Schmid B, Sleytr UB, Bohle B. Natural self-assembly of allergen-S-layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity. Int Arch Allergy Immunol 2009; 149:231-8; PMID:19218815; http://dx.doi.org/10.1159/000199718.
43. Schulke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U, et al. A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. J Allergy Clin Immunol 2011; 128:1340-8, e12; PMID:21872305; http://dx.doi.org/10.1016/j.jaci.2011.07.036.
44. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:1470-6; PMID:16751015; http://dx.doi.org/10.1016/j.jaci.2006.01.040.
45. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206:1941-55; PMID:19667059; http://dx.doi.org/10.1084/jem.20090199.
46. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009; 39:562-70; PMID:19226280; http://dx.doi.org/10.1111/j.1365-2222.2008.03191.x.
47. Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182:6298-306; PMID:19414783; http://dx.doi.org/10.4049/jimmunol.0713622.
48. Crameri R, Kundig TM, Akdis CA. Modular antigentranslocation as a novel vaccine strategy for allergenspecific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:568-73; PMID:19680120; http://dx.doi.org/10.1097/ACI. 0b013e3283310fdf.
49. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23:1804-13; PMID:15734046; http://dx.doi.org/10.1016/j.vaccine.2004.11.010.
50. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19:2534-41; PMID:11257389; http://dx.doi.org/10.1016/S0264- 410X(00)00553-3.
51. Goldman M. Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin Exp Immunol 2007; 147:208-16; PMID:17223960; http://dx.doi.org/10.1111/j.1365- 2249.2006.03296.x.
52. Patel M, Xu D, Kewin P, Choo-Kang B, McSharry C, Thomson NC, et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005; 174:7558-63; PMID:15944255.
53. Lombardi V, Van Overtvelt L, Horiot S, Moussu H, Chabre H, Louise A, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008; 38:1819-29; PMID:18644025.
54. Mascarell L, Van Overtvelt L, Lombardi L. Razafindratsita, Moussu H, Horiot S, Chabre H, Paccaud J-P, Limal D, Moutel S, Bauer J, Chiavaroli C, Moingeon P. A synthetic triacylated pseudodipeptide molecule promotes Th1/T Reg immune responses and enhances tolerance induction via the sublingual route. Vaccine 2007; 26:108-18; PMID:18063445; http://dx.doi.org/10.1016/j.vaccine. 2007.10.050.